Genus comes in on track

Genus, the global animal genetics company, said its full year figures would be in line with expectations after a good performance over the last two months.

The company said pricing had remained firm, with adjusted operating profit improving in line with expectations despite increasing investment in research and growing its management teams.

Profits had improved strongly in Asia, particularly in Russia and China, and in Latin America, it said.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Going forward, the firm expects strong growth in emerging markets, particularly in China.

The group's businesses in North America also performed well due to cost controls and improved royalty income offsetting softness there.

Europe had performed broadly in line with the prior year, it added.